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Introduction: Inflammation is involved in development of lung can-
cer and cardiovascular disease (CVD), and we hypothesize that self-
reported CVD is an independent risk factor for lung cancer.
Methods: Data from the Nord-Trøndelag Health Study (1984–2008) 
linked to the Norwegian Cancer and Death Cause Registry were ana-
lyzed stratified by smoking status. In total, 97,087 persons (1,634,967 
person years) were included (never smokers 567,575 person years, for-
mer smokers 295,685 person years, current smokers 444,922 person 
years, and unknown 326,785 person years) and followed for an average 
of 15 years. The proportional hazard model was applied to estimate the 
hazard ratio (HR) with a 95% confidence interval (CI) for self-reported 
CVD on lung cancer incidence rate adjusted for age, sex, body mass 
index, burden of tobacco smoking and chronic cough with phlegm.
Results: 1080 cases of lung cancer (1.1%) occurred. A total of 5981 
(6.9%) participants had at baseline or developed during follow-up self-
reported CVD. After adjusting for confounders, self-reported CVD was 
an independent risk factor for the development of lung cancer in former 
(HR [95% CI] 1.74 [1.11–2.73]) and current smokers (HR [95% CI] 1.38 
[1.04–1.83]), but not in never smokers (HR [95% CI] 0.87 [0.34–2.23]).
Conclusions: Self-reported CVD was independently associated with 
increased occurrence of lung cancer in former and current smokers. 
CVD may be a novel risk factor for lung cancer screening.
Key Words: Lung cancer, Inflammation, Cardiovascular disease, 
Risk, Epidemiology
(J Thorac Oncol. 2014;9: 940–946)
Lung cancer has the second highest incidence of all can-cers, is the leading cause of cancer mortality,1 and there has 
been only minor improvement in overall five years survival 
during the last decades. In Norway, the overall 5-year survival 
increased from 7.7% to 11.0% and from 11.5% to 14.3% in 
men and women, respectively, from 1969 to 2008. This is 
primarily related to improved curative treatment of limited 
disease.1 Accordingly, early detection of lung cancer and iden-
tification of new indicators of risk or disease development are 
warranted. Tobacco smoking is the major cause of lung cancer, 
but also other factors like sex, age, body mass index (BMI), 
asbestos, and radon are related to the risk of lung cancer.2,3
Inflammation plays a central role in the development 
of both lung cancer4,5 and cardiovascular disease (CVD)6 
and CVD is frequently seen in patients with lung cancer.7 
The high prevalence of CVD in lung cancer patients could 
be because of common risk factors for both diseases (age, 
smoking), but beyond these and genetic/epigenetic factors, 
specific traits associated with CVD could be independent risk 
factors for lung cancer. Chronic inflammation is associated 
with an increased cell turnover with the potential of generat-
ing genetic errors, stimulate angio-neogenesis, and apoptosis8 
and plays a role in the pathogenesis of CVD with an influence 
on all stages of the disease.6
Airway inflammation might also influence lung cancer 
development, for example, chronic obstructive pulmonary 
disease (COPD) has been found to be an independent risk 
factor for lung cancer.9 Both COPD and CVD are associated 
with chronic inflammation10,11 and represent the most preva-
lent comorbidities in lung cancer patients. Still, the specific 
inflammatory processes involved in development of the two 
comorbidities may have independent influence on the occur-
rence of lung cancer. We hypothesized that self-reported CVD 
is an independent risk factor for lung cancer. Our hypothesis 
was studied in a large Norwegian cohort study, the Nord-
Trøndelag Health Study (HUNT study).
MATERIALS AND METHODS
Study Subjects
The HUNT study is a large population-based prospec-
tive cohort study in Norway.12 So far, three surveys have 
been performed, the HUNT1 (1984–1986), the HUNT2 
(1995–1997), and the HUNT3 (2006–2008). All residents 
of the Nord-Trøndelag County, 20 years or older, have been 
invited to each survey. In total, 74,599 (88%), 65,333 (70%), 
and 50,839 (54%) persons attended HUNT1, HUNT2, and 
HUNT3, respectively. In total, 106,456 persons have partici-
pated at least once. In all three surveys, data on demographics, 
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personal and family medical history, and clinical examina-
tions were collected. In January 2009, the total population in 
Nord-Trøndelag counted approximately 130,000 inhabitants.
The present study includes participants from all three 
surveys. Self-reported CVD status at time of participation for 
the persons attending just one survey defined the study groups 
for comparison. Participants, who attended more than one sur-
vey and had altered self-reported CVD status from “no” to 
“yes” between the surveys, changed group allocation for the 
rest of the follow up, Figure 1.
The observation period was from the day of inclusion 
in the HUNT study (HUNT1, HUNT2, or HUNT3) until the 
event of lung cancer, death, at the time the answer regarding 
self-reported CVD changed from “self-reported CVD no” 
to “self-reported CVD yes” in HUNT2 or HUNT3 or at the 
end of the study at December 31, 2008, which ever occurred 
first. Persons with an observation period less than 1 year were 
excluded from the study. Data from HUNT were merged 
with data from the Cancer Registry of Norway (CRN) and 
the Norwegian Cause of Death Registry at Statistics Norway 
(SSB)13 that are mandatory registries in Norway (Fig. 1).
Outcome Variable
Lung Cancer
Lung cancer diagnosis was based on the classifica-
tion system established by the World Health Organization, 
Histological Typing of Lung Tumours, second edition.14 
Both patients with non–small-cell lung cancer (NSCLC) and 
small-cell lung cancer (SCLC) were included in this study. 
Norwegian law dictates that all cases of cancer must be regis-
tered in the Cancer Registry of Norway.
Exposure Variable
Self-reported CVD
The definition of self-reported CVD was based on base-
line questionnaires in all three surveys. Self-reported CVD 
was defined by the answer “yes” to one or more of the fol-
lowing questions: “Do you have or have you had myocardial 
infarction?,” “Do you have or have you had angina pectoris?,” 
or “Do you have or have you had stroke?”.
Confounders
BMI (four categories according to the World Health 
Organization criteria; underweight = <18.5 kg/m2, normal 
weight = ≥18.5 to <25 kg/m2, overweight = ≥25 to <30 kg/m2, 
obesity ≥ 30 kg/m2) and sex were included in the proportional 
hazard regression model. Age was included as a time variable in 
the model. In addition, we included chronic cough and phlegm, 
as a proxy variable for chronic inflammation in the airways into 
the model. Chronic cough and phlegm was based on the ques-
tions “Do you normally cough in the morning?” and “Do you 
normally expectorate phlegm from your chest in the morning?” 
in HUNT1, whereas in HUNT2 and HUNT3 it was based on 
the questions “Do you cough daily during periods of the year?” 
and “Do you usually bring up phlegm when coughing?”. In the 
analyses of former and current smokers, the burden of smoking 
was included and dichotomized into light smokers (1–20 pack 
years) and heavy smokers (>20 pack years).
FIGURE 1.  Flowchart of the inclu-
sion over the period from HUNT1 to 
2008. Numbers of participants that 
changed the cardiovascular disease 
(CVD) status during observation (in 
HUNT2 or HUNT3) are marked with 
a circle and were included as persons 
being exposed from the time they 
answered yes to the question defin-
ing CVD status.
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Questions on tobacco smoking were included in a fol-
low-up questionnaire in HUNT1, whereas in HUNT2 and 
HUNT3 these were included in the main baseline question-
naire. This influenced the response rate on these questions; 
78%, 98%, and 97% in HUNT1, HUNT2, and HUNT3, 
respectively. In the whole HUNT population, smoking sta-
tus was known in n = 86,674 (81%) persons. Missing data on 
pack years (burden of smoking) n = 10,432 (22%) and chronic 
cough with phlegm n = 23,013 (22%) reduced the number of 
persons eligible for complete cases analyses.
Statistical Methods
All analyses were performed separately for never, former 
and current smokers. The characteristics according to smoking 
status and self-reported CVD status were compared by χ2 test 
for categorical variables and t test for continuous variables.
The effect of self-reported CVD on lung cancer inci-
dence rates was estimated by proportional hazard regression 
models controlling for confounders and including age as a time 
variable in all analyses and therefore not as an own covariate 
in the model. Because of a high number of cases having miss-
ing values on chronic cough with phlegm or burden of tobacco 
smoking, maximum likelihood estimation was performed 
on 3 groups: (1) complete cases and (2) cases with a miss-
ing value on either chronic cough with phlegm or (3) cases 
with a missing value on burden of tobacco smoking. For cases 
with missing values on chronic cough with phlegm, a logistic 
regression model with self-reported CVD, sex, BMI, burden of 
tobacco smoking, and age at the time of inclusion as covariates 
was used. For cases with missing values on burden of tobacco 
smoking, a logistic regression model with self-reported CVD, 
sex, BMI, chronic cough with phlegm, and age at time of inclu-
sion as covariates was used. A Wald test was used to compare 
the effect of self-reported CVD for complete cases and cases 
with the 1 or the other missing values mentioned above.
Potential interactions and proportional hazard assump-
tion between the exposure variable and confounders were 
tested. The hazard ratio (HR) is reported with 95% confidence 
interval (CI). Because we did not adjust for multiple testing a 
P value less than 0.01 was defined as statistically significant.
Except for survival analysis, which was performed with 
the statistical program R version 2.13.1 (October 26, 2012) for 
Windows, all statistical analyses were performed with the sta-
tistical program PASW version 19 (Predictive Analytics Soft 
Ware IBM Corporation, NY).
Ethical Considerations
The Regional Committee for Medical and Health 
Research Ethics approved the current study (REK# 
2010/1081). All participants in HUNT have signed informed 
consent for use of their data in research.
RESULTS
Study Participants
A total of 97,087 persons (52% females and 48% males) 
were included in the study. A complete dataset was available 
in 65,828 persons, in never smokers n = 33,121 (86% of all 
never smokers), former smokers n = 11,776 (56% of all for-
mer smokers), and current smokers n = 20,931 (78% of all 
current smokers). The participants were followed for an aver-
age of 15 years at risk, for a total of 1,634,967 person years. 
The mean age at inclusion was 46 ± 18 years.
During follow up, 1080 cases (1.1%) of lung cancer 
occurred (20% SCLC, 80% NSCLC, 721 cases (1.5%) in men, 
and 359 cases (0.7%) in women. The mean age at diagnosis 
of lung cancer was 70.2 ± 10 years for both sexes. The cumu-
lative incidence of lung cancer among never smokers, former 
smokers, current smokers, and unclassified was 72 (0.2%), 182 
(0.9%), 698 (2.6%), and 128 (1.2%), respectively. Baseline 
characteristics of the study population are shown in Table 1.
Self-Reported CVD and Lung Cancer
In never smokers, 37 cases of lung cancer/100,000 per-
son years were seen in those with self-reported CVD versus 
12 cases/100,000 person years in those without self-reported 
CVD. In former and current smokers, 280 cases of lung can-
cer/100,000 person years were seen in those with self-reported 
CVD versus 64 cases of lung cancer/100,000 person years in 
those without self-reported CVD. Persons with self-reported 
CVD were older than those without self-reported CVD, 
70.4 ± 11.2 versus 43.7 ± 17.3 years. There were more former 
and current smokers among persons with self-reported CVD. 
Men had more often self-reported CVD. There was no differ-
ence in the stage (metastatic versus non metastatic disease and 
the histology (NSCLC versus SCLC in lung cancer patients 
with self-reported CVD compared with those patients without 
self-reported CVD (data not shown).
Results from the Regression Models
In univariate regression model, former (HR: 2.47, 95% 
CI: 1.77–3.45) and current smokers (HR: 1.59, 95% CI: 1.26–
2.01) with self-reported CVD were at higher risk for lung 
lancer but not never smokers with self-reported CVD (HR: 
1.04, 95% CI: 0.41–2.67), compared with those without self-
reported CVD (Fig. 2).
After adjustment for sex, BMI, burden of tobacco 
smoking, and chronic cough with phlegm, former and cur-
rent smokers with self-reported CVD were still at higher risk 
(1.4–1.7) getting lung cancer (Tables 2–4). The Wald test did 
not show any significant change of the estimate of the HR for 
self-reported CVD, in never, former, and current smokers, 
comparing results from cases with missing data with results 
from analyses including missing cases and complete cases. 
In a separate analysis of cases with unknown smoking status 
(n = 17,433) and after adjustment for BMI and sex, the HR 
for self-reported CVD was (HR [95% CI] 1.80 [1.12–2.90]).
Among never and current smokers, no interactions were 
found between self-reported CVD and confounders. In former 
smokers, however, the impact of self-reported CVD on the risk 
of lung cancer was four times higher in light smokers com-
pared with heavy smokers (P = 0.001). No major deviation 
from the proportional hazard function was found. All analy-
ses were recalculated with three and five categories for pack 
years. The results remained unchanged in the three groups 
(never, former, and current smokers) (results not shown).
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DISCUSSION
The present study indicates that self-reported CVD is 
an independent risk factor for lung cancer in former and cur-
rent smokers. Adjusting for other risk factors like BMI, sex, 
chronic cough, or phlegm, as a proxy variable for chronic 
inflammation in the airways, and the burden of smoking, 
weakened the associations, but CVD was still an indepen-
dent risk factor for lung cancer. To our knowledge, this is the 
first study investigating the association between self-reported 
CVD and the incidence of lung cancer.
CVD is prevalent among patients with lung cancer, 
approximately 20%7,15 and chronic inflammation seems to be a 
TABLE 1.   Baseline Characteristics (BMI, Sex, Chronic Cough With Phlegm, Person Years, and Age at Inclusion), for the Study 
Population with Available Smoking Status
Never Smokers  
(n = 38,656)
Former Smokers  
(n = 20,914)
Current Smokers  
(n = 26,894)
CVD CVD CVD
Yes No Yes No Yes No
n = 2205 n = 36,451 n = 2304 n = 18,610 n = 1472 n = 25,422
BMI* <18.5 1 1 1 1 2 2
≥18.5 to <25.0 30 51 29 47 45 58
≥25.0 to <30.0 45 36 50 40 42 31
≥30.0 23 13 20 12 12 9
Sex Female 69 59 18 43 25 51
Male 31 41 82 57 75 49
Chronic cough Yes 5 3 8 4 18 10
with phlegm
Smoking Light smoker — — 60 89 53 84
Heavy smoker — — 40 11 47 16
Person years† 14.6 ± 8.3 14.1 ± 9.0 16.5 ± 7.8
Age at inclusion† 44.2 ± 19.1 46.9 ± 17.2 42.4 ± 15.6
Figures are percentage of participants in each group, The HUNT study.
*Kg/m2.
†Mean and standard deviation.
CVD, cardiovascular disease; BMI, body mass index; n, numbers.
FIGURE 2.  Plot of proportion “not 
getting lung cancer” by age for never 
smokers (n = 38,656), former smok-
ers (n = 20,914), and current smokers 
(n=26,894), separately presented for 
persons with (n = 5981) and without 
cardiovascular disease (n = 80,483). 
The HUNT study.
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major pathophysiologic factor in the development of CVD.16,17 
We found a positive association between self-reported CVD 
and lung cancer in both former and current smokers, but not in 
never smokers in our study population. This might be indicate 
that smoking and CVD could have an additive or synergistic 
effect in the development lung cancer. However, because the 
analyses with increasing numbers of categories for pack years 
did not changes the results, we think residual confounding 
by smoking is a minor problem in this study. The number of 
lung cancer cases in former smokers was small. Accordingly, 
the results in this group may be biased by a low power. This 
inconsistence may also be explained by competing risk, that 
is, heavy former smokers may die of other diseases before 
they get lung cancer.
Because smoking causes both lung cancer and CVD, 
our results could be confounded by the effect of smoking. 
Stratification by smoking status and adjustment for smoking 
burden (light and heavy smokers) did, however, not change 
the estimates. Concerning the interaction between the burden 
of tobacco smoking and self-reported CVD in former smok-
ers, this may depend on bias related to self-reported smoking. 
Those with less education and/or heavy smokers are likely to 
report inaccurate number of cigarettes per day18 and this is 
especially seen in former smokers.19
Chronic inflammation plays a key role in the underly-
ing pathophysiology of both CVD and lung cancer and could 
theoretically explain our findings, at least to some extent. 
Chronic inflammation is associated with an increased cell 
turnover with the potential of generating genetic errors, and 
stimulating angio-neogenesis and apoptosis.8 Different types 
of chronic inflammatory diseases are positively associated 
with cancers, for example, ankylosing spondylitis and kid-
ney cancer,20 inflammatory bowel disease and colon cancer,21 
and COPD and lung cancer.9,22 Genetic factors responsible for 
our immune response may have impact on who will develop 
specific inflammations leading to COPD and/or CVD. Our 
genetic constitution may be crucial for the susceptibility of 
a distinct inflammation and in the next step for the develop-
ment of lung cancer and may explain why only a minor per-
centage of tobacco smokers develop COPD and lung cancer. 
A certain exposure may be necessary, but not sufficient to 
develop a specific disease, and may illustrate the importance 
of the interplay between both exposure and genetic constitu-
tion or susceptibility to cancer. Other factors such as nutrition, 
vitamins, physical activity, and indoor air pollution may also 
contribute to the development of lung cancer23–25 and are not 
tested in our study.
However, our observation in the current study showing 
that self-reported CVD in former and current smokers may 
represent an additional risk factor for lung cancer is noteworthy 
TABLE 2.   Cox Regression Model to Analyze the Association 
Between CVD and Lung Cancer in Never Smokers, Adjusted 
for BMI, Sex, and Chronic Cough with Phlegm, With Age 
Used as the Time Variable
HR 95% CI
CVD 0.87 0.34–2.23
BMI*
  <18.5 4.57 0.60–34.76
  ≥18.5 to <25.0 1
  ≥25.0 to <30.0 2.13 1.16–3.92
  ≥30.0 1.03 0.39–2.69
Sex
  Male vs. female 2.34 1.37–3.96
Chronic cough with phlegm
  Yes vs. no 2.51 0.78–8.09
n = 33,121, 58 cases of lung cancer.
*Kg/m2
CVD, cardiovascular disease; BMI, body mass index; n, numbers; HR, hazard ratio; 
CI, confidence interval.
TABLE 3.   Cox Regression Model to Analyze the Association 
Between CVD and Lung Cancer in Former Smokers, Adjusted 
for BMI, Sex, Burden of Smoking and Chronic Cough with 
Phlegm, with Age Used as the Time Variable
HR 95% CI
CVD 1.74 1.11–2.73
BMI*
  <18.5 2.60 0.36–19.01
  ≥18.5 to <25.0 1
  ≥25.0 to <30.0 0.81 0.53–1.25
  ≥30.0 0.80 0.43–1.48
Sex
  Male vs. female 1.43 0.82–2.49
Chronic cough with phlegm
  Yes vs. no 0.88 0.32–2.42
  Heavy vs. light smoker 3.56 2.33–5.45
n = 11,776, 102 cases of lung cancer.
*Kg/m2
CVD, cardiovascular disease; BMI, body mass index; n, numbers; HR, hazard ratio; 
CI, confidence interval.
TABLE 4.   Cox Regression Model to Analyze the Association 
Between CVD and Lung Cancer in Current Smokers, Adjusted 
for BMI, Sex, Burden of Smoking and Chronic Cough with 
Phlegm, with Age Used as the Time Variable
HR 95% CI
CVD 1.38 1.04–1.83
BMI*
  <18.5 1.36 0.67–2.75
  ≥18.5 to <25.0 1
  ≥25.0 to <30.0 0.98 0.81–1.17
  ≥30.0 0.89 0.65–1.23
Sex
  Male vs. female 1.09 0.90–1.31
Chronic cough with phlegm
  Yes vs. no 1.55 1.22–1.97
Heavy vs. light smoker 2.11 1.75–2.54
n = 20,931, 521 cases of lung cancer.
*Kg/m2
CVD, cardiovascular disease; BMI, body mass index; n, numbers; HR, hazard ratio; 
CI, confidence interval.
945Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 7, July 2014 Risk of lung cancer
but not surprising given the high prevalence of CVD in patients 
with lung cancer.7 Smokers with self-reported CVD seem to 
be at higher risk of developing lung cancer compared with 
smokers without self-reported CVD. Thus, it may have a sig-
nificant influence on the detection and definition of the popula-
tion that would benefit from screening for lung cancer. To date, 
screening for lung cancer is not recommended in Europe. The 
National Lung Screening Trail, the largest and most reliable 
screening study for lung cancer to date, included people 55–74 
years of age having smoked 30 pack years or more (7% of all 
smokers in United States).26 A worldwide debate discussing 
future widespread screening is running, and the hottest ques-
tion is how to define the risk group for screening. CVD are 
highly prevalent in smokers, and this subgroup may be a new 
and important risk group for lung cancer screening, making the 
results of the present study highly relevant.
Strengths and Limitations
This study has several strengths. First, the present study 
is a cohort study from a well-defined geographic area, with a 
stable and large number of inhabitants and a high participant 
rate, especially in the first two surveys, 88% and 70%, respec-
tively. Second, the HUNT study includes comprehensive data 
on known risk factors and confounders for CVD and lung 
cancer which were included in the analyses in the present 
study. Third, our study has a long observation period with a 
median at 15.3 years. Fourth, the use of our national cancer 
registry, with obligatory registration of all new cases of can-
cer, ensures a high validity of the cancer diagnosis and cause 
of death. Fifth, representativity, where the prevalence of lung 
cancer, distribution of SCLC and NSCLC, and median age of 
the lung cancer patients of 71 years is in line with other stud-
ies and indicates high external validity of the present study.
One limitation is the relatively high number of  missing 
data regarding smoking status, pack years and data about 
chronic cough with phlegm. However, including cases with 
missing data did not change the results. Self-reported CVD 
diagnosis in our study is based on questionnaire and we can-
not rule out that we have missed patients with CVD among 
nonresponders a fact that may bias our results. Further, we 
have adjusted for confounders at baseline but not included 
changes during observation, which might bias the results.
Most patients with lung cancer have attended the 
HUNT1 study (69%). In HUNT1, no blood samples were 
taken so we have not the opportunity to analyze inflammation 
markers like IL-6, neither Vitamin D nor calcium.
CONCLUSION
Self-reported CVD is associated with a higher risk of 
lung cancer in former smokers and current smokers indepen-
dent of the burden of tobacco smoking, whereas no associa-
tion was found in never smokers. CVD may be a novel risk 
factor for lung cancer screening, a task for future studies.
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